Read this manager's filing book
Disclosed positions
Eversept Partners, LP: source evidence dated 2026-08-15T03:59:59.999Z.
- Issuer
- UNITED THERAPEUTICS CORP DEL
- Ticker
- UTHR
- Class
- COM
- Reported value
- $155,867,152
- Reported amount
- 287,668
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0001697013-26-000005Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
| UNITED THERAPEUTICS CORP DEL | UTHR | COM | $155,867,152 | 287,668 | SH | None |
| ABIVAX SA | ABVX | SPONSORED ADS | $121,783,649 | 913,880 | SH | None |
| ENCOMPASS HEALTH CORP | EHC | COM | $103,800,973 | 1,026,919 | SH | None |
| ENSIGN GROUP INC | ENSG | COM | $96,513,264 | 602,079 | SH | None |
| VERA THERAPEUTICS INC | VERA | CL A | $94,949,961 | 2,212,770 | SH | None |
| INVESCO QQQ TR | QQQ | UNIT SER 1 | $72,609,040 | 98,600 | SH | Put |
| CELLDEX THERAPEUTICS INC NEW | CLDX | COM NEW | $66,454,865 | 1,785,941 | SH | None |
| SYNDAX PHARMACEUTICALS INC | SNDX | COM | $61,168,871 | 2,798,210 | SH | None |
| BROOKDALE SR LIVING INC | BKD | COM | $54,649,202 | 3,396,470 | SH | None |
| IONIS PHARMACEUTICALS INC | IONS | COM | $52,702,794 | 664,684 | SH | None |
| NATERA INC | NTRA | COM | $47,722,810 | 175,807 | SH | None |
| TRAVERE THERAPEUTICS INC | TVTX | COM | $45,389,656 | 798,973 | SH | None |
| CARETRUST REIT INC | CTRE | COM | $43,255,805 | 1,072,015 | SH | None |
| HCA HEALTHCARE INC | HCA | COM | $38,307,472 | 98,252 | SH | None |
| VAXCYTE INC | PCVX | COM | $36,619,110 | 629,952 | SH | None |
| LIQUIDIA CORPORATION | LQDA | COM NEW | $34,176,424 | 428,652 | SH | None |
| COMMUNITY HEALTH SYS INC NEW | CYH | COM | $26,267,680 | 7,864,575 | SH | None |
| GSK PLC | GSK | SPONSORED ADR | $25,257,686 | 481,833 | SH | None |
| CHEMED CORP NEW | CHE | COM | $24,462,062 | 52,523 | SH | None |
| ELI LILLY & CO | LLY | COM | $24,127,734 | 20,116 | SH | None |
| GERON CORP | GERN | COM | $23,958,300 | 18,717,422 | SH | None |
| VIKING THERAPEUTICS INC | VKTX | COM | $23,519,987 | 602,922 | SH | None |
| OMEGA HEALTHCARE INVS INC | OHI | COM | $23,055,521 | 483,547 | SH | None |
| INSULET CORP | PODD | COM | $22,657,236 | 148,816 | SH | None |
| TENET HEALTHCARE CORP | THC | COM NEW | $21,364,349 | 114,199 | SH | None |
| UNITEDHEALTH GROUP INC | UNH | COM | $21,257,396 | 51,145 | SH | None |
| WELLTOWER INC | WELL | COM | $19,817,205 | 87,312 | SH | None |
| BETA BIONICS INC | BBNX | COM | $19,578,740 | 1,249,441 | SH | None |
| COGENT BIOSCIENCES INC | COGT | COM | $18,972,094 | 490,235 | SH | None |
| BIOCRYST PHARMACEUTICALS INC | BCRX | COM | $18,656,530 | 1,865,653 | SH | None |
| MOLINA HEALTHCARE INC | MOH | COM | $18,431,848 | 80,594 | SH | None |
| PENNANT GROUP INC | PNTG | COM | $17,007,050 | 460,272 | SH | None |
| LTC PPTYS INC | LTC | COM | $16,173,608 | 420,640 | SH | None |
| INSMED INC | INSM | COM PAR $.01 | $15,908,664 | 149,209 | SH | None |
| VIRIDIAN THERAPEUTICS INC | VRDN | COM | $15,268,079 | 831,142 | SH | None |
| BIOMARIN PHARMACEUTICAL INC | BMRN | COM | $14,282,513 | 249,607 | SH | None |
| AMN HEALTHCARE SVCS INC | AMN | COM | $13,871,548 | 428,531 | SH | None |
| CELCUITY INC | CELC | COM | $13,384,141 | 127,931 | SH | None |
| PHARVARIS N V | PHVS | COM | $13,361,124 | 386,383 | SH | None |
| CYTOMX THERAPEUTICS INC. | CTMX | COM | $13,344,364 | 3,558,497 | SH | None |
| HUMANA INC | HUM | COM | $12,381,745 | 31,171 | SH | None |
| XENON PHARMACEUTICALS INC | XENE | COM | $11,862,672 | 196,532 | SH | None |
| CORVUS PHARMACEUTICALS INC | CRVS | COM | $11,175,030 | 747,994 | SH | None |
| ASCENDIS PHARMA A/S | ASND | ORD SHS | $11,101,153 | 41,621 | SH | None |
| BRUKER CORP | BRKR | COM | $11,006,561 | 182,894 | SH | None |
| MODERNA INC | MRNA | COM | $10,653,104 | 152,122 | SH | None |
| STRUCTURE THERAPEUTICS INC | GPCR | SPONSORED ADS | $10,535,528 | 196,302 | SH | None |
| INSMED INC | INSM | COM PAR $.01 | $10,299,492 | 96,600 | SH | Call |
| DEFINIUM THERAPEUTICS INC | DFTX | COM SHS | $10,216,382 | 217,185 | SH | None |
| COMPASS PATHWAYS PLC | CMPS | SPONSORED ADS | $9,520,474 | 672,825 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 1 positions lack a resolved ticker and 5 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.